JP2014110814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014110814A5 JP2014110814A5 JP2014057616A JP2014057616A JP2014110814A5 JP 2014110814 A5 JP2014110814 A5 JP 2014110814A5 JP 2014057616 A JP2014057616 A JP 2014057616A JP 2014057616 A JP2014057616 A JP 2014057616A JP 2014110814 A5 JP2014110814 A5 JP 2014110814A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- mouse
- gene
- gene segment
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 89
- 210000004027 cell Anatomy 0.000 claims 23
- 238000003780 insertion Methods 0.000 claims 14
- 230000037431 insertion Effects 0.000 claims 14
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 7
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 210000001161 mammalian embryo Anatomy 0.000 claims 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446895P | 2011-02-25 | 2011-02-25 | |
| US61/446,895 | 2011-02-25 | ||
| US201161497650P | 2011-06-16 | 2011-06-16 | |
| US61/497,650 | 2011-06-16 | ||
| US201261595200P | 2012-02-06 | 2012-02-06 | |
| US61/595,200 | 2012-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Division JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015036588A Division JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014110814A JP2014110814A (ja) | 2014-06-19 |
| JP2014110814A5 true JP2014110814A5 (enExample) | 2015-04-09 |
| JP5866127B2 JP5866127B2 (ja) | 2016-02-17 |
Family
ID=45998616
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Pending JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
| JP2014057616A Active JP5866127B2 (ja) | 2011-02-25 | 2014-03-20 | Ａｄａｍ６マウス |
| JP2015036588A Withdrawn JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
| JP2016088848A Withdrawn JP2016135143A (ja) | 2011-02-25 | 2016-04-27 | Ａｄａｍ６マウス |
| JP2018107070A Withdrawn JP2018143250A (ja) | 2011-02-25 | 2018-06-04 | Ａｄａｍ６マウス |
| JP2019127562A Withdrawn JP2019187446A (ja) | 2011-02-25 | 2019-07-09 | Ａｄａｍ６マウス |
| JP2022029501A Pending JP2022071051A (ja) | 2011-02-25 | 2022-02-28 | Ａｄａｍ６マウス |
| JP2024212173A Pending JP2025032218A (ja) | 2011-02-25 | 2024-12-05 | Ａｄａｍ６マウス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Pending JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015036588A Withdrawn JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
| JP2016088848A Withdrawn JP2016135143A (ja) | 2011-02-25 | 2016-04-27 | Ａｄａｍ６マウス |
| JP2018107070A Withdrawn JP2018143250A (ja) | 2011-02-25 | 2018-06-04 | Ａｄａｍ６マウス |
| JP2019127562A Withdrawn JP2019187446A (ja) | 2011-02-25 | 2019-07-09 | Ａｄａｍ６マウス |
| JP2022029501A Pending JP2022071051A (ja) | 2011-02-25 | 2022-02-28 | Ａｄａｍ６マウス |
| JP2024212173A Pending JP2025032218A (ja) | 2011-02-25 | 2024-12-05 | Ａｄａｍ６マウス |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US8642835B2 (enExample) |
| EP (7) | EP3744850A1 (enExample) |
| JP (8) | JP2014507137A (enExample) |
| KR (1) | KR101387377B1 (enExample) |
| CN (2) | CN105861548B (enExample) |
| AU (5) | AU2012243291B2 (enExample) |
| BR (1) | BR112013021771B1 (enExample) |
| CA (1) | CA2820824A1 (enExample) |
| CY (5) | CY1116301T1 (enExample) |
| DE (5) | DE14154967T1 (enExample) |
| DK (6) | DK2813573T1 (enExample) |
| ES (6) | ES2758974T5 (enExample) |
| FI (3) | FI2738258T4 (enExample) |
| HR (5) | HRP20192311T4 (enExample) |
| HU (5) | HUE062552T2 (enExample) |
| IL (4) | IL226727A (enExample) |
| IN (1) | IN2013CN07629A (enExample) |
| LT (4) | LT2738258T (enExample) |
| ME (3) | ME02106B (enExample) |
| MX (3) | MX375115B (enExample) |
| MY (1) | MY172713A (enExample) |
| NZ (2) | NZ776770A (enExample) |
| PL (5) | PL2738259T3 (enExample) |
| PT (5) | PT2738259T (enExample) |
| RS (5) | RS59413B2 (enExample) |
| RU (2) | RU2582261C2 (enExample) |
| SG (4) | SG192933A1 (enExample) |
| SI (5) | SI2578688T2 (enExample) |
| SM (5) | SMT202300173T1 (enExample) |
| WO (1) | WO2012141798A1 (enExample) |
| ZA (1) | ZA201305998B (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| WO2006008548A2 (en) | 2004-07-22 | 2006-01-26 | Erasmus University Medical Centre Rotterdam | Binding molecules |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| RU2612903C2 (ru) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| DK2813573T1 (da) | 2011-02-25 | 2015-01-12 | Regeneron Pharma | ADAM6 mus |
| EP2739300B1 (en) | 2011-07-05 | 2019-06-19 | Duke University | N-terminal deleted gp120 immunogens |
| HUE068728T2 (hu) * | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2850745C (en) | 2011-10-03 | 2022-12-13 | Duke University | Vaccine |
| PL3216871T3 (pl) * | 2011-10-17 | 2022-03-21 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
| US20180295821A1 (en) * | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| MX378871B (es) | 2011-12-20 | 2025-03-10 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| PL2809150T3 (pl) * | 2012-02-01 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| KR102213535B1 (ko) | 2012-03-16 | 2021-02-08 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
| EP3348140B1 (en) | 2012-03-16 | 2020-12-30 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| EP2858487B1 (en) * | 2012-06-12 | 2019-10-23 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| MX357061B (es) | 2013-02-06 | 2018-06-25 | Regeneron Pharma | Diseño de inmunogenos a base de linaje de celulas b con animales humanizados. |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| EP2967012B1 (en) * | 2013-03-14 | 2020-09-16 | Erasmus University Medical Center Rotterdam | Transgenic non-human mammal for antibody production |
| WO2014141192A1 (en) * | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| JP6267986B2 (ja) * | 2014-02-13 | 2018-01-24 | 株式会社特殊免疫研究所 | ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法 |
| RU2016141307A (ru) * | 2014-03-21 | 2018-04-24 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, которые вырабатывают однодоменные связывающие белки |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| IL260526B2 (en) * | 2016-01-13 | 2023-10-01 | Regeneron Pharma | Rodents having an engineered heavy chain diversity region |
| EP3416479A1 (en) | 2016-02-16 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a mutant kynureninase gene |
| WO2017201476A1 (en) | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
| IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| MA53935A (fr) | 2016-11-04 | 2021-12-22 | Regeneron Pharma | Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée |
| US11122042B1 (en) | 2017-05-12 | 2021-09-14 | F5 Networks, Inc. | Methods for dynamically managing user access control and devices thereof |
| CN110809583A (zh) | 2017-06-07 | 2020-02-18 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
| PL3720279T3 (pl) | 2017-12-05 | 2023-01-16 | Regeneron Pharmaceuticals, Inc. | Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| EP3768079A4 (en) | 2018-03-21 | 2021-12-08 | Crystal Bioscience Inc. | TRANSGENIC CHICKEN THAT PRODUCES HUMAN ANTIBODIES |
| SMT202500038T1 (it) | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| JP7420730B2 (ja) | 2018-04-06 | 2024-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 |
| MX2020012350A (es) | 2018-05-17 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-cd63, conjugados y usos de estos. |
| WO2019240999A1 (en) * | 2018-06-13 | 2019-12-19 | Crystal Bioscience Inc. | Camelization of a human variable domain by gene conversion |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| AU2020226445B2 (en) | 2019-02-18 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
| EP3927153A1 (en) | 2019-02-22 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
| CA3136478A1 (en) | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| DK3785536T4 (da) * | 2019-08-28 | 2025-10-27 | Trianni Inc | Adam6-knockin-mus |
| WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| AU2021283564B2 (en) | 2020-06-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
| EP4211155A1 (en) | 2020-09-11 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| EP4262373A1 (en) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| AU2021409906A1 (en) | 2020-12-23 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
| JP7758739B2 (ja) | 2020-12-23 | 2025-10-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンカー改変型抗体をコードする核酸およびその使用 |
| CN117177993B (zh) | 2021-04-20 | 2025-06-20 | 瑞泽恩制药公司 | 针对artemin的人抗体及其使用方法 |
| EP4554977A1 (en) | 2022-07-12 | 2025-05-21 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
| AU2024220647A1 (en) | 2023-02-13 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle related disorders with anti-human cacng1 antibodies |
| WO2024229105A1 (en) | 2023-05-02 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025055311A1 (zh) | 2023-09-15 | 2025-03-20 | 赛业（苏州）生物科技有限公司 | 用于制备抗体的基因修饰小鼠及其制备方法 |
| KR20250151517A (ko) * | 2023-09-15 | 2025-10-21 | 사이어젠 바이오싸이언스이즈 (쑤저우) 인코퍼레이티드 | 항체 제조를 위한 유전자 변형 마우스 및 이의 제조 방법 |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| KR20250108092A (ko) * | 2024-01-02 | 2025-07-15 | 젬파마테크 컴퍼니 리미티드 | 인간화 항체를 생성하는 동물 모델 및 그 제작 방법 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH08503617A (ja) * | 1992-12-01 | 1996-04-23 | プロテイン デザイン ラブズ、インコーポレーテッド | Ｌ−セレクチンに反応性のヒト化抗体 |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| CN1203922A (zh) * | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| RU10506U1 (ru) | 1999-04-08 | 1999-08-16 | Кривулин Виталий Николаевич | Ручной культиватор |
| JP2003501016A (ja) * | 1999-05-27 | 2003-01-14 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Ａｄａｍのポリヌクレオチドおよびポリペプチド |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| WO2003031656A1 (en) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
| US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
| JP4099646B2 (ja) | 2002-06-04 | 2008-06-11 | 株式会社安川電機 | ボイスコイルモータ |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP1739691B1 (en) | 2005-06-30 | 2008-12-03 | Borealis Technology Oy | Outer sheath layer for power or communication cable |
| EP2505058A1 (en) * | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
| CN112690250B (zh) * | 2008-12-18 | 2024-03-08 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| JP5399140B2 (ja) * | 2009-06-18 | 2014-01-29 | 株式会社タイトー | モールス信号通信システム |
| EP3028565B1 (en) * | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| US8754287B2 (en) | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| NZ605966A (en) * | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
| DK2813573T1 (da) | 2011-02-25 | 2015-01-12 | Regeneron Pharma | ADAM6 mus |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| PL3216871T3 (pl) | 2011-10-17 | 2022-03-21 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
| GB201118579D0 (en) | 2011-10-27 | 2011-12-07 | Micromass Ltd | Control of ion populations |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| MX378871B (es) | 2011-12-20 | 2025-03-10 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| EP2858487B1 (en) | 2012-06-12 | 2019-10-23 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
-
2012
- 2012-02-24 DK DK14176593.3T patent/DK2813573T1/da unknown
- 2012-02-24 NZ NZ776770A patent/NZ776770A/en unknown
- 2012-02-24 CN CN201610204885.6A patent/CN105861548B/zh active Active
- 2012-02-24 PL PL14154967T patent/PL2738259T3/pl unknown
- 2012-02-24 RS RS20191337A patent/RS59413B2/sr unknown
- 2012-02-24 DK DK12192727.1T patent/DK2578688T4/da active
- 2012-02-24 HU HUE22156414A patent/HUE062552T2/hu unknown
- 2012-02-24 HR HRP20192311TT patent/HRP20192311T4/hr unknown
- 2012-02-24 NZ NZ731926A patent/NZ731926A/en unknown
- 2012-02-24 RS RS20230475A patent/RS64280B1/sr unknown
- 2012-02-24 EP EP20170540.7A patent/EP3744850A1/en active Pending
- 2012-02-24 JP JP2013550677A patent/JP2014507137A/ja active Pending
- 2012-02-24 ES ES14154918T patent/ES2758974T5/es active Active
- 2012-02-24 PT PT141549675T patent/PT2738259T/pt unknown
- 2012-02-24 EP EP22156414.9A patent/EP4067496B1/en active Active
- 2012-02-24 LT LTEP14154918.8T patent/LT2738258T/lt unknown
- 2012-02-24 DK DK22156414.9T patent/DK4067496T5/da active
- 2012-02-24 ME MEP-2015-35A patent/ME02106B/me unknown
- 2012-02-24 DE DE14154967.5T patent/DE14154967T1/de active Pending
- 2012-02-24 DE DE14176593.3T patent/DE14176593T1/de active Pending
- 2012-02-24 EP EP14154967.5A patent/EP2738259B1/en active Active
- 2012-02-24 RU RU2013125717/10A patent/RU2582261C2/ru active
- 2012-02-24 ME MEP2019272 patent/ME03537B/xx unknown
- 2012-02-24 DK DK12716101.6T patent/DK2550363T3/en active
- 2012-02-24 IN IN7629CHN2013 patent/IN2013CN07629A/en unknown
- 2012-02-24 SI SI201231675T patent/SI2578688T2/sl unknown
- 2012-02-24 PT PT221564149T patent/PT4067496T/pt unknown
- 2012-02-24 HR HRP20150262AT patent/HRP20150262T1/hr unknown
- 2012-02-24 ME MEP-2020-41A patent/ME03732B/me unknown
- 2012-02-24 EP EP12192727.1A patent/EP2578688B2/en active Active
- 2012-02-24 SI SI201230157T patent/SI2550363T1/sl unknown
- 2012-02-24 HU HUE12192727A patent/HUE046081T2/hu unknown
- 2012-02-24 SG SG2013064159A patent/SG192933A1/en unknown
- 2012-02-24 HR HRP20191895TT patent/HRP20191895T4/hr unknown
- 2012-02-24 HU HUE14154918A patent/HUE046746T2/hu unknown
- 2012-02-24 US US13/404,075 patent/US8642835B2/en active Active
- 2012-02-24 CN CN201280010457.XA patent/CN103429746B/zh active Active
- 2012-02-24 PT PT141549188T patent/PT2738258T/pt unknown
- 2012-02-24 SM SM20230173T patent/SMT202300173T1/it unknown
- 2012-02-24 FI FIEP14154918.8T patent/FI2738258T4/fi active
- 2012-02-24 SM SM20200112T patent/SMT202000112T1/it unknown
- 2012-02-24 DE DE12716101T patent/DE12716101T1/de active Pending
- 2012-02-24 MX MX2016013717A patent/MX375115B/es unknown
- 2012-02-24 PL PL12716101T patent/PL2550363T3/pl unknown
- 2012-02-24 MY MYPI2013003123A patent/MY172713A/en unknown
- 2012-02-24 DE DE12192727T patent/DE12192727T1/de active Pending
- 2012-02-24 PL PL22156414.9T patent/PL4067496T3/pl unknown
- 2012-02-24 RU RU2016109443A patent/RU2722373C2/ru not_active Application Discontinuation
- 2012-02-24 SM SM20190581T patent/SMT201900581T1/it unknown
- 2012-02-24 PL PL14154918.8T patent/PL2738258T5/pl unknown
- 2012-02-24 SG SG10201913155QA patent/SG10201913155QA/en unknown
- 2012-02-24 SG SG10201913160QA patent/SG10201913160QA/en unknown
- 2012-02-24 PL PL12192727.1T patent/PL2578688T5/pl unknown
- 2012-02-24 DK DK14154918.8T patent/DK2738258T4/da active
- 2012-02-24 CA CA2820824A patent/CA2820824A1/en not_active Withdrawn
- 2012-02-24 SI SI201231739T patent/SI2738259T1/sl unknown
- 2012-02-24 SI SI201232031T patent/SI4067496T1/sl unknown
- 2012-02-24 ES ES14176593T patent/ES2805364T3/es active Active
- 2012-02-24 HU HUE12716101A patent/HUE024534T2/hu unknown
- 2012-02-24 SM SM20190744T patent/SMT201900744T1/it unknown
- 2012-02-24 FI FIEP12192727.1T patent/FI2578688T4/fi active
- 2012-02-24 EP EP14176593.3A patent/EP2813573B1/en active Active
- 2012-02-24 DK DK14154967.5T patent/DK2738259T3/da active
- 2012-02-24 MX MX2013009649A patent/MX343009B/es active IP Right Grant
- 2012-02-24 EP EP14154918.8A patent/EP2738258B2/en active Active
- 2012-02-24 LT LTEP22156414.9T patent/LT4067496T/lt unknown
- 2012-02-24 BR BR112013021771-5A patent/BR112013021771B1/pt active IP Right Grant
- 2012-02-24 LT LTEP14154967.5T patent/LT2738259T/lt unknown
- 2012-02-24 SI SI201231712T patent/SI2738258T2/sl unknown
- 2012-02-24 RS RS20191599A patent/RS59661B2/sr unknown
- 2012-02-24 SG SG10201405135RA patent/SG10201405135RA/en unknown
- 2012-02-24 PT PT121927271T patent/PT2578688T/pt unknown
- 2012-02-24 RS RS20150163A patent/RS53880B1/sr unknown
- 2012-02-24 LT LT12192727T patent/LT2578688T/lt unknown
- 2012-02-24 ES ES22156414T patent/ES2946169T3/es active Active
- 2012-02-24 ES ES12716101.6T patent/ES2532487T3/es active Active
- 2012-02-24 DE DE14154918.8T patent/DE14154918T1/de active Pending
- 2012-02-24 ES ES12192727T patent/ES2748832T5/es active Active
- 2012-02-24 PT PT12716101T patent/PT2550363E/pt unknown
- 2012-02-24 HR HRP20230526TT patent/HRP20230526T1/hr unknown
- 2012-02-24 WO PCT/US2012/026416 patent/WO2012141798A1/en not_active Ceased
- 2012-02-24 ES ES14154967T patent/ES2770424T3/es active Active
- 2012-02-24 AU AU2012243291A patent/AU2012243291B2/en active Active
- 2012-02-24 HU HUE14154967A patent/HUE047687T2/hu unknown
- 2012-02-24 RS RS20200177A patent/RS59929B1/sr unknown
- 2012-02-24 EP EP12716101.6A patent/EP2550363B1/en active Active
- 2012-02-24 KR KR1020137025191A patent/KR101387377B1/ko active Active
-
2013
- 2013-05-09 US US13/890,519 patent/US8697940B2/en active Active
- 2013-06-04 IL IL226727A patent/IL226727A/en active IP Right Grant
- 2013-08-08 ZA ZA2013/05998A patent/ZA201305998B/en unknown
- 2013-08-21 MX MX2020009714A patent/MX2020009714A/es unknown
-
2014
- 2014-02-27 US US14/192,051 patent/US9932408B2/en active Active
- 2014-03-20 JP JP2014057616A patent/JP5866127B2/ja active Active
-
2015
- 2015-01-20 US US14/600,829 patent/US10072095B2/en active Active
- 2015-02-26 JP JP2015036588A patent/JP2015107131A/ja not_active Withdrawn
- 2015-03-03 CY CY20151100221T patent/CY1116301T1/el unknown
- 2015-03-11 SM SM201500061T patent/SMT201500061B/xx unknown
- 2015-04-09 US US14/682,859 patent/US9944716B2/en active Active
- 2015-10-07 AU AU2015238806A patent/AU2015238806A1/en not_active Abandoned
-
2016
- 2016-04-27 JP JP2016088848A patent/JP2016135143A/ja not_active Withdrawn
-
2017
- 2017-10-26 AU AU2017251802A patent/AU2017251802A1/en not_active Abandoned
-
2018
- 2018-06-04 JP JP2018107070A patent/JP2018143250A/ja not_active Withdrawn
- 2018-08-09 US US16/059,922 patent/US10905109B2/en active Active
- 2018-08-09 US US16/059,871 patent/US10577430B2/en active Active
- 2018-08-09 US US16/059,884 patent/US10694725B2/en active Active
- 2018-08-09 US US16/059,821 patent/US10905108B2/en active Active
- 2018-08-20 IL IL261243A patent/IL261243B/en active IP Right Grant
-
2019
- 2019-07-09 JP JP2019127562A patent/JP2019187446A/ja not_active Withdrawn
- 2019-08-13 IL IL268671A patent/IL268671B/en active IP Right Grant
- 2019-09-19 CY CY20191100988T patent/CY1122205T1/el unknown
- 2019-10-23 CY CY20191101104T patent/CY1122459T1/el unknown
-
2020
- 2020-01-22 CY CY20201100054T patent/CY1122820T1/el unknown
- 2020-02-21 AU AU2020201279A patent/AU2020201279A1/en not_active Abandoned
- 2020-02-21 HR HRP20200294TT patent/HRP20200294T1/hr unknown
- 2020-04-16 IL IL273986A patent/IL273986B/en active IP Right Grant
- 2020-12-21 US US17/129,708 patent/US11950578B2/en active Active
- 2020-12-21 US US17/129,706 patent/US12207628B2/en active Active
-
2022
- 2022-02-11 FI FIEP22156414.9T patent/FI4067496T3/fi active
- 2022-02-28 JP JP2022029501A patent/JP2022071051A/ja active Pending
- 2022-07-22 AU AU2022206806A patent/AU2022206806B2/en active Active
-
2023
- 2023-05-31 CY CY20231100256T patent/CY1126091T1/el unknown
-
2024
- 2024-03-06 US US18/597,797 patent/US20240306617A1/en active Pending
- 2024-12-05 JP JP2024212173A patent/JP2025032218A/ja active Pending